Enhancing Patient Compliance: Developing an ExtendedRelease Anti-Epileptic Drug
The current immediate-release (IR) tablet formulation for epilepsy1 , available in Europe, requires multiple doses due to the drug’s short half-life, making it inconvenient for patients. This case study explores the development of an extended-release (ER) formulation by Syngene’s Formulation Development team for an anti-epileptic drug, aimed at reducing the need for frequent dosing and […]
Syngene Enhances Bispecific Antibody Production
The GEM-DIMER™ platform is a proprietary technology developed by Hinge Bio. This technology allows the production of antibodies with enhanced multivalency and multispecificity, enabling the simultaneous targeting of multiple diseaseassociated antigens
Pharmaceutical Development of a Broad-Spectrum Antibacterial Candidate for Multidrug-Resistant Infections
The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top ten global public health threats. Despite concerted global efforts, AMR infections caused 4.95 Mn deaths in 2019. A clinical-stage biopharmaceutical company has been working on AMR since 2016 in collaboration with Syngene.
(N-1) Perfusion Technology
In the dynamic world of biomanufacturing, the quest for improved efficiency and productivity continues to shape industry advancements. N-1 Perfusion Technology is a cutting edge innovation designed to enhance protein yield, particularly antibodies, which are critical for therapeutic applications.
In silico immunogenicity assessment for peptides with unnatural amino acids
The peptide therapeutics market comprises over 80 approved drugs, with many generics introduced upon patent expiration. The production of generics typically introduces additional peptide impurities. These impurities could trigger an undesired immune response, affecting safety and efficacy in patients.
Enhancing Prodrug Solubility with Syngene’s SynVent Platform
Prodrugs are medications that, once administered, are metabolized in the body to release the active ingredient. They help to improve a medication’s effectiveness and can in some cases avoid certain side effects or toxicities.
SynWeave™ : Redefining Cell Line Development for Next-Generation Biologics
The biopharmaceutical industry witnessed significant innovation, with many new recombinant protein therapeutics receiving FDA approval. However, these therapies are often costly, emphasizing the need for greater efficiency and productivity.
Powering Global Pharma Innovation: The Rise of Indian CROs
India supplies more than 20% of the world’s generic medicines, reaching over 200 countries. It provides 40% of generic drugs used in the U.S. and 80% of antiretrovirals globally, reinforcing its pivotal role in affordable global healthcare.
Peptides: A Scientific Revolution in Modern Medicine
Learn about GLP-1 peptides and their revolutionary impact on modern medicine, and how Syngene is enabling this advancement through its state-of-the-art peptide synthesis facility.
The Syngene Advantage: Accelerating Progress Through Integrated Technology Transfer
At Syngene, technology transfer is a seamless, cross-site collaboration, accelerating your journey from concept to commercialization. This video showcases the synergy between our Bangalore (BSEZ) and Mangalore (MSEZ) campuses, driven by robust systems and deep expertise. Our facilities are built for uncompromising quality, proudly GMP certified, 21 CFR compliant, and USFDA approved, ensuring global standards […]